Table 2.
Healthy conditions | Osteoarthritis conditions | GLP-1 analogues effects | Signaling pathways involved in GLP-1 effects |
---|---|---|---|
Homeostasis | Inflammation Cytokines synthesis | Anti-inflammatory (10, 16,30–32, 49–50, 63) | NF-κB PKA/CREB MAPK |
Cartilage synthesis Matrix production | Hypertrophic differentiation ER stress | Anabolism/chondrogenic differentiation (43) Anti-oxydative stress (16) | ? ? PI3K/Akt MAPK |
Cartilage degradation | Catabolism Apoptosis Decreased Autophagy Senescence | Anti-catabolic (ROS, AGEs) Prevent apoptosis (35) ? ? | PI3K/Akt MAPK PI3K/Akt AMPK ? ? |
Osteogenesis | Subchondral bone remodeling Osteophytes Reduced mineralization | Proliferation/ Differentiation (62–66) Maturation (69) Migration (63) Autophagy | Erk 1/2 MAPK β-catenin RANKL Wnt/β-catenin ? TGF-β |
Adipogenesis | Adipokines synthesis Fatty acid synthesis Inflammation | Proliferation/ Differentiation (75,77) Fatty acid degeneration (47) Anti-inflammatory | PKC ? NF-κB PKA/CREB Erk 1/2 |
Nociception | Neuro-inflammation Pain Neuronal apoptosis | Neurotrophic/ Neuroprotector (92) Anti-inflammatory (86) Improved pain sensitivity (88) (release of β-endorphin) Analgesic (85) Anti-apoptotic (90) | Erk 1/2 NF-κB PKA/CREB cAMP MAPK Erk 1/2 PI3K/Akt AMPK |